Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Acquires $16,000.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson acquired 1,000 shares of the company’s stock in a transaction dated Thursday, July 18th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $16,000.00. Following the completion of the acquisition, the vice president now directly owns 261,348 shares of the company’s stock, valued at $4,181,568. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Greenwich LifeSciences Trading Down 3.1 %

Shares of NASDAQ GLSI opened at $15.55 on Thursday. Greenwich LifeSciences, Inc. has a 12 month low of $7.58 and a 12 month high of $21.44. The stock has a market cap of $200.28 million, a price-to-earnings ratio of -21.60 and a beta of 1.64. The company has a 50 day simple moving average of $15.20 and a two-hundred day simple moving average of $13.92.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings data on Monday, May 20th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. Analysts forecast that Greenwich LifeSciences, Inc. will post -0.75 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Greenwich LifeSciences in a report on Wednesday, May 22nd.

Institutional Trading of Greenwich LifeSciences

A hedge fund recently raised its stake in Greenwich LifeSciences stock. Vanguard Group Inc. lifted its stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 223,102 shares of the company’s stock after purchasing an additional 1,420 shares during the period. Vanguard Group Inc. owned about 1.73% of Greenwich LifeSciences worth $4,449,000 as of its most recent filing with the Securities & Exchange Commission. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.